Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 21, 2024

Early Evaluation of ctDNA as a Marker of Therapeutic Efficacy and Prognosis in Patients With Breast Cancer During Primary Systemic Therapy

The Breast

 

Additional Info

The Breast
Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy
Breast 2024 Aug 01;76(xx)103738, R Wang, B Wang, H Zhang, X Liao, B Shi, Y Zhou, C Zhou, Y Yan, W Zhang, K Wang, G Ge, Y Ren, X Tang, B Gan, J He, L Niu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading